Implications of Extending the ADHD Age-of-Onset Criterion to Age 12: Results from a Prospectively Studied Birth Cohort

 This article is discussed by Dr. Russell A. Barkley in an editorial on page 205.

 This research was supported by the UK Medical Research Council (G9806489, G0100527, and G0601483).

 Disclosure: Dr. Polanczyk has served as a speaker for Novartis and is a recipient of a 2008 National Alliance of Research on Schizophrenia and Depression (NARSAD) Young Investigator Award. Dr. Kollins has received research support and/or consultant fees from Addrenex Pharmaceuticals, Otsuka Pharmaceuticals, Shire Pharmaceuticals, the National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), and Environmental Protection Agency (EPA). Dr. Rohde has served as a speaker and/or consultant for Eli Lilly, Janssen-Cilag, and Novartis in the last 3 years. Currently, his only industry-related activity is taking part in the advisory board/speakers' bureau for Eli Lilly and Novartis. The ADHD and Juvenile Bipolar Disorder Outpatient Programs chaired by him have received unrestricted educational and research support from the following pharmaceutical companies in the last 3 years: Abbott, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Novartis, and Shire. Dr. Houts, Caspi, and Moffitt report no biomedical financial interests or potential conflicts of interest.

PII: S0890-8567(09)00071-9

doi:10.1016/j.jaac.2009.12.014

© 2010 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.